Aethlon Medical, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AEMD Nasdaq 2834 www.aethlonmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aethlon Medical, Inc.

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 - Nov 7th, 2025 6:01 am
AEMD: Early Oncology Trial Data Looks Promising - Oct 21st, 2025 3:49 am
AEMD: Oncology Trial Advances as Early Data Looks Promising - Oct 10th, 2025 7:06 am
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial - Oct 7th, 2025 6:01 am
Aethlon Medical announces pricing of $4.5M common stock, warrant offering - Sep 5th, 2025 7:25 am
Aethlon Medical Announces Pricing of $4.5 Million Public Offering - Sep 4th, 2025 7:15 am
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) - Sep 3rd, 2025 6:01 am
BC-Most Active Stocks - Aug 21st, 2025 8:30 am
AEMD: Cohort 2 Enrollment Open; Initial Cohort 1 Data Analysis Expected Next Month - Aug 19th, 2025 3:44 am
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ... - Aug 15th, 2025 3:01 pm
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update - Aug 13th, 2025 2:15 pm
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025 - Aug 5th, 2025 6:01 am
AEMD: No SAEs in Cohort 1 Post-Hemopurifier Treatment; Progressing Trial to Cohort 2 - Jul 17th, 2025 5:32 am
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort - Jul 15th, 2025 6:01 am
AEMD: Progressing & Expanding Clinical & Pre-Clinical Activities in Cost Efficient Manner - Jul 2nd, 2025 8:34 am
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update - Jun 26th, 2025 2:15 pm
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025 - Jun 20th, 2025 6:01 am
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial - Jun 18th, 2025 6:01 am
Presenting on Emerging Growth Conference 83 Day 1 on June 17; Register to live stream - Jun 16th, 2025 5:00 am
AEMD: Virtual Meeting With Management, Upcoming Presentation of Data in Long Covid - Jun 12th, 2025 10:07 am